The pathogenic importance of IL-4/IL-13 signaling in AD has been recently highlighted because its blockage by dupilumab, a specific anti-IL-4 receptor α (IL-4Rα, IL4R) antibody, successfully improves skin inflammation in patients with AD [17]. The gene discussed is IL13; the disease is dermatitis.